Phase 2 Alzheimer's Disease Trial, Recruiting NCT05597124 Sponsor: Rutgers, The State University of New Jersey Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT05597124
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You self-identify as African American or Black
  • You are 60 years of age or older
  • You are able to speak, read, and understand English
  • You are able to be available for the full length of the study
  • You are able to walk on your own without a wheelchair, walker, or cane
  • You currently do less than 60 minutes of physical activity per week (based on a short activity questionnaire)
  • You score within a specific range on a telephone-based memory and thinking test called the TICS-M (confirm with trial site)
  • You score between 20 and 26 on an in-person memory and thinking test called the MoCA
  • You have written approval from your own doctor to take part in physical activity for this study

Who may not be able to join:

  • You have color blindness, as some study tasks use color as a guide
  • You have been diagnosed with any neurological condition, including chronic headaches or nerve damage in the hands or feet
  • You have been diagnosed with, or report having, major depression, schizophrenia, delusional disorder, schizoaffective disorder, psychosis, or other significant mental health conditions that could affect your ability to complete the study
  • You have had a substance use disorder or received treatment for one in the past five years
  • You have undergone chemotherapy or radiation treatment for cancer
  • You are planning to have general anesthesia at any point during the study
  • You have a Geriatric Depression Scale score of 5 or higher (confirm with trial site)
  • You have conditions that make exercise unsafe, such as bone or joint problems, a heart attack, heart bypass surgery, angioplasty, or other heart-related events in the past year
  • You are currently being treated for heart failure, chest pain (angina), uncontrolled irregular heartbeat, or blood clots in the legs
  • You have uncontrolled high blood pressure with readings above 180/110 mmHg at rest

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark A. Gluck, PhD, Rutgers, The State University of New Jersey - Newark campus

Phone: (973) 944-0775

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Rutgers, The State University of New Jersey
Registry
ClinicalTrials.gov
Start date
20 April 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Generalization Performance on the Concurrent Discrimination and Transfer Task; Generalization Performance on the Acquired Equivalence Task; Medial Temporal Lobe Neural Flexibility

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov